Weight Loss Drugs: A Game Changer in the Fight Against Obesity - New InsightAce Analytic Report Investigates
Weight Loss Drugs: A Game Changer in the Fight Against Obesity - New InsightAce Analytic Report Investigates
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
Structure Therapeutics (GPCR) Rallying on Obesity Drug Data [Yahoo! Finance]
Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares